Eosinophilic Esophagitis: Update on Clinicopathological Manifestations and Pathophysiology

Glenn T. Furuta

Disclosures

Curr Opin Gastroenterol. 2011;27(4):383-388. 

In This Article

Abstract and Introduction

Abstract

Purpose of review Over the course of the last year, a number of studies have brought new insights into the clinical presentation, pathogenesis, and treatment of eosinophilic esophagitis, some of which will be summarized here.
Recent findings This swell of research and clinical need resulted in revision of the 2007 Consensus Recommendations. In addition, new insights into key clinicopathological features including symptoms such as feeding dysfunction and histological quantification of eosinophil extracellular granules are presented. The advancement of the field is strongly supported by blinded and placebo-controlled studies of IL-5 and oral viscous budesonide as well as new large studies examining the safety of dilation.
Summary Overall, these studies set the stage for new methodologies to understand the pathophysiology of eosinophilic esophagitis and development of novel therapies.

Introduction

The last year has brought new insights into this enigmatic disease. New consensus recommendations captured phenotypic diversities associated with eosinophilic esophagitis (EoE) and have placed more emphasis on refining clinical and histological features. The clinical impact of inflammation on esophageal function is undergoing more scrutiny with novel technologies and in basic laboratory models. Studies on treatments are reaching beyond case series to now include promising placebo and blinded studies.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....